Imaging and imaging-guided interventions in the diagnosis and management of hepatocellular carcinoma (HCC)-review of evidence

Iranian Journal of Radiology

Volumn 9, Issue 4, 2012, Pages 167-177

  Ghanaati, Hossein ^a,b   Alavian, Seyed Moayed ^c   Jafarian, Ali ^a   Daryani, Nasser Ebrahimi ^a   Nassiri Toosi, Mohsen ^a   Jalali, Amir Hossein ^b   Shakiba, Madjid ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carcinoma; Chemoembolization; Hepatocellular; Interventional; Iran; Radiology; Risk Factors; Therapeutic

Indexed keywords

ACETIC ACID; ALCOHOL;

CANCER DIAGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; ECHOGRAPHY; HUMAN; INTERVENTIONAL RADIOLOGY; LASER SURGERY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MICROWAVE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; RADIOFREQUENCY ABLATION; REVIEW;

EID: 84872862144     PISSN: 17351065     EISSN: 20082711     Source Type: Journal    
DOI: 10.5812/iranjradiol.8242     Document Type: Review

References (94)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002 CA Cancer J Clin. 2005;55(2):74-108.
2. Fani A, Fani I, Eshrati B, Samadian P, Fani P, Ghoreyshi Y, et al. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B and C in Markazi province, Iran. Hepat Mon. 2007;7(3):149-52.
3. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24(4):899-919.
4. Fathimoghaddam F, Hedayati-Moghaddam MR, Bidkhori HR, Ahmadi S, Sima HR. The prevalence of hepatitis B antigen-pos-itivity in the general population of Mashhad, Iran. Hepat Mon. 2011;11(5):346-50.
5. Alavian SM, Hajariazdeh B, Ahmadzad Asl M, Kabir A, Bagheri Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon. 2008;8(4):281-94.
6. Blum HE. Hepatocellular carcinoma: HCC. Hepat Mon. 2011;11(2):69-70.
7. Saiedi Hosseini SY. Risk factors and incidence of hepatocellular carcinoma in southeast iran. Hepat Mon. 2011;11(8):666-7.
8. Zhang Q, Cao G. Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. Hepat Mon. 2011;11(2):86-91.
9. Choi BI. Advances of imaging for hepatocellular carcinoma. Oncology. 2010;78(Suppl 1):46-52.
10. Ghanaati H, Firouznia K, Vaziri Bozorg SM, Ghasemi Esfe AR, Motevallei M, Abedini MR, et al. Nintinol self-expandable metallic stenting in management of malignant obstructive jaundice: a case series. Hepat Mon. 2010;10(1):57-61.
11. Blum HE, Spangenberg HC. Hepatocellular Carcinoma: An Update. Arch Iran Med. 2007;10(3):361-71.
12. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Annals of surgery. 1995;221(3):291-8.
13. Alsowmely AM, Hodgson HJ. Non-surgical treatment of hepatocellular carcinoma. Aliment pharma therap. 2002;16(1):1-15.
14. Ghanaati H, Firouznia K, Jalali AH, Shakiba M. Advances of interventional radiology in treatment of hepatobiliary diseases in Iran. Hepat Mon. 2011;11(7):507-10.
15. Yu SC, Yeung DT, So NM. Imaging features of hepatocellular carcinoma. Clin Radiol. 2004;59(2):145-56.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-36.
17. Lee KH, O'Malley ME, Kachura JR, Haider M, Hanbidge A. Pictorial essay. Hepatocellular carcinoma: imaging and imaging-guided intervention. AJR American J roentgen. 2003;180(4):1015-22.
18. Ghanaati H, Alavian SM, Firouznia K, Abedini MR, Mohammadi-fard M, Jalali AH, et al. Tailoring of Interventional Procedures for HCC Patients-Review Article. Iran J Radiol. 2010;7(3):129-43.
19. Nicolau C, Bianchi L, Vilana R. Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening, and intervention. Semin Ultrasound CTMR. 2002;23(1):3-18.
20. Vogl TJ, Eichler K, Zangos S, Mack M, Hammerstingl R. [Hepatocellular carcinoma: Role of imaging diagnostics in detection, intervention and follow-up]. Rofo. 2002;174(11):1358-68.
21. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. ScandJ Gastroenterol. 2003;38(7):770-8.
22. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985;89(2):259-66.
23. Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986;90(2):289-98.
24. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival Hepatology. 1992;16(1):132-7.
25. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22(2):432-8.
26. Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. American j roentgen. 2006;186(5):1401-12.
27. Fahey BJ, Nelson RC, Bradway DP, Hsu SJ, Dumont DM, Trahey GE. In vivo visualization of abdominal malignancies with acoustic radiation force elastography. Phys Med Biolo. 2008;53(1):279-93.
28. Kiba T, Numata K, Kitamura T, Morita K, Saito S, Sekihara H. Combination therapy of percutaneous mitoxantrone injection, percutaneous ethanol injection, and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastasis. Hepatogastroenterology. 2001;48(38):427-31.
29. Dodd GD, Baron RL, Oliver JH, Federle MP. Spectrum of imaging findings of the liver in end-stage cirrhosis: Part II, focal abnormalities. AJR American J roentgen. 1999;173(5):1185-92.
30. Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol clinic North Americ. 2009;47(1):161-78.
31. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--ini-tial experience. Radiology. 2007;243(3):736-43.
32. Ippolito D, Sironi S, Pozzi M, Antolini L, Ratti L, Alberzoni C, et al. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Academic radiol. 2008;15(7):919-27.
33. Kan Z, Kobayashi S, Phongkitkarun S, Charnsangavej C. Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. Radiol. 2005;237(1):144-50.
34. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13(2):120-5.
35. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatol-ogy. 2003;38(4):1034-42.
36. Hashemi M, Ghavami S. Hepatocellular recurrence after orthotopic liver transplantation: Is combination of alpha-fetoprotein and glypican-3 a reliable marker?: Hepatocellular recurrence after orthotopic liver trasplantation Hepat Mon. 2011;11(3):155-6.
37. Harisinghani MG, Hahn PF. Computed tomography and magnetic resonance imaging evaluation of liver cancer Gastroenterol Clin North Am. 2002;31(3):759-76.
38. Lee DH, Kim SH, Lee JM, Park HS, Lee JY, Yi NJ, et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings. Invest Radiol. 2009;44(6):311-21.
39. Kubaska S, Sahani DV, Saini S, Hahn PF, Halpern E. Dual contrast enhanced magnetic resonance imaging of the liver with super-paramagnetic iron oxide followed by gadolinium for lesion detection and characterization. Clin Radiol. 2001;56(5):410-5.
40. Taouli B, Ehman RL, Reeder SB, et al. Advanced MRI methods for assessment of chronic liver disease. American j roentgenology. 2009;193(1):14-27.
41. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis. 2009;27(2):114-24.
42. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250(2):466-73.
43. Ghanaati H, Firouznia K, Motevalli M, Mirdamadi L, Jalali AH. Fluoroscopic versus conventional computed tomography-guided biopsy. IranJRadiol. 2008;5(1):39-42.
44. Nassiri-Toosi M, Ghanati H, Azmoudeh Ardalan F, Agdarkosh H, Safai SR, Lak M, et al. Assessment of safety and Efficacy of Transjugular liver biopsy as a diagnostic method in adult patients with congenital bleeding disorders with HCV infection. Iran J Radiol. 2004;1(1-2):73-8.
45. Guan YS, Sun L, Zhou XP, Li X, Zheng XH. Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. WorldJ Gastroenterol. 2004;10(24):3543-8.
46. Livraghi T. Role of percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Dig Dis. 2001;19(4):; p. 292-300
47. Guan YS, Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006;5(4):495-500.
48. Di Stasi M, Buscarini L, Livraghi T, Giorgio A, Salmi A, De Sio I. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol. 1997;32(11):; p. 1168-73
49. Hasegawa S, Yamasaki N, Hiwaki T, Sako K, Komorizono Y, Baba Y, et al. Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer. 1999;86(9):; p. 1682-90
50. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L. Hepatocellular carcinoma and cirrhosis in 746 patients: longterm results of percutaneous ethanol injection. Radiology. 1995;197(1):101-8.
51. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapac-cini GL, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992;69(4):925-9.
52. Allgaier HP, Galandi D, Zuber I, Blum HE. Radiofrequency thermal ablation of hepatocellular carcinoma. Dig Dis. 2001;19(4):301-10.
53. Lu MD, Chen JW, Xie XY, Liu L, Huang XQ, Liang LJ. Hepatocellular carcinoma: US-guided percutaneous microwave coagulation therapy. Radiology. 2001;221(1):167-72.
54. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology. 1998;27(1):67-72.
55. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54(8):1151-6.
56. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. j hepato. 2010;52(3):380-8.
57. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J. 2008;14(2): p. 117-22
58. Iannitti DA, Dupuy DE, Mayo-Smith WW, Murphy B. Hepatic radiofrequency ablation. Arch Surg. 2002;137(4):422-6.
59. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78(Suppl 1):113-24.
60. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2009;104(2):; p. 514-24
61. Ferrari FS, Megliola A, Scorzelli A, Stella A, Vigni F, Drudi FM, et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. Radiol Med. 2007;112(3):377-93.
62. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annal surgery. 2006;243(3):321-8.
63. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129(1):122-30.
64. Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 1994;(3):817-25.
65. Dong B, Liang P, Yu X, Su L, Yu D, Cheng Z, et al. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. American j roent-geno. 2003;180(6):1547-55.
66. Gough-Palmer AL, Gedroyc WM. Laser ablation of hepatocellular carcinoma--a review. World J Gastroenterol. 2008;14(47):7170-4.
67. Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Annals surgery. 2003;237(2):171-9.
68. Pacella CM, Bizzarri G, Francica G, Forlini G, Petrolati A, Valle D. Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. J hepatol. 2006;44(5):902-9.
69. Zhou XD, Tang ZY. Cryotherapy for primary liver cancer. Semin Surg Oncol. 1998;14(2):171-4.
70. Weaver ML, Atkinson D, Zemel R. Hepatic cryosurgery in treating colorectal metastases. Cancer. 1995;76(2):210-4.
71. Crews KA, Kuhn JA, McCarty TM, Fisher TL, Goldstein RM, Preskitt JT. Cryosurgical ablation of hepatic tumors. Am J Surg. 1997;174(6):614-7.
72. Maleux G, van Malenstein H, Vandecaveye V, Heye S, Vaninbroukx J, Nevens F, et al. Transcatheter chemoembolization of unresect-able hepatocellular carcinoma: current knowledge and future directions. Dig Dis. 2009;27(2):157-63.
73. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6-25.
74. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72(3):505-16.
75. Plentz RR, Lankisch TO, Basturk M, Muller CC, Kirchhoff T, Gebel M, et al. Prospective analysis of German patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembo-lization with or without prophylactic antibiotic therapy. J gastro hepato. 2005;20(7):1134-6.
76. Jaeger HJ, Mehring UM, Castaneda F, Hasse F, Blumhardt G, Loehlein D, et al. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol. 1996;19(6):388-96.
77. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47-54.
78. Shin SW. The current practice of transarterial chemoemboliza-tion for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10(5):425-34.
79. Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs. 2004;15(5):427-37.
80. Llado L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoem-bolization. Cancer. 2000;88(1):50-7.
81. O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembo-lization for inoperable hepatocellular carcinoma. British J surg. 2003;90(3):325-31.
82. Clark TW. Chemical ablation of liver cancer. Techniques in vascular and interventional radiology. [Review]. 2007;10(1):58-63.
83. Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, et al. Combination therapy with transcatheter arterial chemoem-bolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer. 2001;92(6):1516-24.
84. Bartolozzi C, Lencioni R, Caramella D, Vignali C, Cioni R, Mazzeo S, et al. Treatment of large HCC: transcatheter arterial chemo-embolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology. 1995;197(3):812-8.
85. Gasparini D, Sponza M, Marzio A, Zanardi R, Bazzocchi M, Cemal Y. Combined treatment, TACE and RF ablation, in HCC: preliminary results. Radiol Med. 2002;104(5-6):412-20.
86. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial che-moembolization (TACE) as a combined therapy for unresect-able non-early hepatocellular carcinoma (HCC). Europ Radiol. 2006;16(3):661-9.
87. Takamura M, Murakami T, Shibata T, Ishida T, Niinobu T, Kawata S, et al. Microwave coagulation therapy with interruption of hepatic blood in-or outflow: an experimental study. J Vasc Interven Radiol: JVIR. 2001;12(5):619-22.
88. Shibata T, Murakami T, Ogata N. Percutaneous microwave coagulation therapy for patients with primary and metastatic hepatic tumors during interruption of hepatic blood flow. Cancer. 2000;88(2):302-11.
89. Seki T, Tamai T, Nakagawa T, Imamura M, Nishimura A, Yamashiki N, et al. Combination therapy with transcatheter arterial chemo-embolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer. 2000;89(6):1245-51.
90. Pacella CM, Bizzarri G, Cecconi P, Caspani B, Magnolfi F, Bianchini A, et al. Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology. 2001;219(3):669-78.
91. Ferrari FS, Stella A, Gambacorta D, Magnolfi F, Fantozzi F, Pas-quinucci P. Treatment of large hepatocellular carcinoma: comparison between techniques and long term results. Radiol Med. 2004;108(4):356-71.
92. Seki T, Tamai T, Nakagawa T, Imamura M, Nishimura A, Yama-shiki N, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma Cancer. 2009;89(6):1245-51.
93. Pacella CM, Bizzarri G, Cecconi P, Caspani B, Magnolfi F, Bianchini A, et al. Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology. 2001;219(3):669-78.
94. Ferrari FS, Stella A, Gambacorta D, Magnolfi F, Fantozzi F, Pasqui-nucci P, et al. Treatment of large hepatocellular carcinoma: comparison between techniques and long term results. Radiol Med. 2004;108(4):356-71.